Novel Therapies In Head And Neck Cancer Beyond The Horizon

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types Discusses the application of immunotherapy to treat rare types of head and neck cancer Presents updated information on targeted therapies, specifically focusing on skin cancer in the region

This book is a complete guide to the management of head and neck cancer. Divided into five sections, the text begins with discussion on pre-treatment assessment and evaluation. Section two covers management of numerous different head and neck cancers, from oral and larynx, to temporal bone, saliva gland, thyroid, and many more. A complete chapter is dedicated to robotic surgery. The following sections detail management of tumour-like lesions, reconstructive surgery, and post-treatment care and rehabilitation. Authored by recognised experts in the field, the comprehensive text is further enhanced by clinical images and figures. Key points Comprehensive guide to management of head and neck cancer Complete chapter dedicated to robotic surgery Discusses reconstructive surgery and post-treatment care Includes images and figures to enhance text

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Strategies for overcoming chemotherapy resistance in cervical cancer highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book has a strong focus on strategies to reverse chemotherapy resistance as well as strategies for early detection of the resistance, enhancing precision oncology in terms of patient care and maximizing patient management. The book also looks at virally induced resistance to chemotherapy and recommends combination therapies that can maximize the reversal of this resistance. In 10 chapters Strategies for overcoming chemotherapy resistance in cervical cancer not only gives an overview of cervical cancer and chemotherapy as treatment, but it also investigates resistance to chemotherapy and the treatment for resistance. It defines the treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into the future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence. This book is a valuable resource for health professionals, scientists and researchers, oncologists, virologists, health practitioners, medical and graduate students, and all those who wish to broaden their knowledge in the allied field. Discusses strategies to reverse and detect resistance to chemotherapy at an early stage Investigates the applications of Artificial Intelligence in the study of cervical chemotherapy resistance Presents research and applications developed to overcome cancer resistance

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field